Find recruiting clinical trials for MS in the UK � including relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS). See your DMT pathway and where trials fit in.
Free to use � Live data from ClinicalTrials.gov � Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Initial disease-modifying therapy after diagnosis
Standard: Interferon beta, Glatiramer acetate, Dimethyl fumarate, or Teriflunomide
After suboptimal response or breakthrough disease activity
Standard: Natalizumab, Fingolimod, Ocrelizumab, or Ofatumumab
Rapidly evolving or aggressive disease course
Standard: Alemtuzumab, Ocrelizumab, or Natalizumab
Secondary or primary progressive disease � fewer approved treatments, trials especially important
Standard: Siponimod (SPMS), Ocrelizumab (PPMS), or clinical trial
About 85% of MS diagnoses. Characterised by episodes of new or worsening symptoms (relapses) followed by periods of recovery (remission). Most DMTs are approved for this form.
Develops in many people with RRMS over time. Steady progression of disability with or without relapses. Fewer treatment options � clinical trials are especially important.
About 10-15% of MS cases. Steady progression from onset without clear relapses. Ocrelizumab is the only approved DMT � trials are critical for new options.
Loading trials from ClinicalTrials.gov...
Novel approaches include BTK inhibitors (Evobrutinib, Tolebrutinib), anti-CD20 therapies, remyelination agents, neuroprotective drugs, and stem cell therapy. Several Phase 3 trials are running in UK centres.
Yes. Haematopoietic stem cell transplantation (HSCT) is being studied in several UK trials for aggressive relapsing MS. It aims to reset the immune system and can halt disease activity in suitable patients.
Yes. Progressive MS (primary and secondary progressive) has historically had fewer treatment options, but new trials specifically target progressive disease with BTK inhibitors, stem cell therapy, and neuroprotective agents.
Use our search above to find trials that match your condition and location. Review the eligibility criteria carefully.
Talk to your GP or specialist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing. They will guide you through screening.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.